Alexander Sapir
Chief Executive Officer at FULCRUM THERAPEUTICS, INC.
Net worth: 410 262 $ as of 31/03/2024
Profile
Mr. Alexander C.
Sapir is a President, Chief Executive Officer & Director at Fulcrum Therapeutics, Inc., an Independent Director at PhaseBio Pharmaceuticals, Inc. and a Chief Executive Officer & Director at ReViral Ltd.
He is on the Board of Directors at Fulcrum Therapeutics, Inc., PhaseBio Pharmaceuticals, Inc. and ReViral Ltd.
Mr. Sapir was previously employed as a President, Chief Executive Officer & Director by Dova Pharmaceuticals, Inc., an Executive Vice President-Marketing & Sales by United Therapeutics Corp., and a Senior Director-Marketing by Guilford Pharmaceuticals, Inc. He received his undergraduate degree from Franklin & Marshall College and an MBA from Harvard Business School.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 31/03/2024 | 43,460 ( 0.07% ) | 410 262 $ | 31/03/2024 | |
| 19/05/2023 | 3,750 ( 0.01% ) | - $ | 31/01/2024 |
Alexander Sapir active positions
| Companies | Position | Start |
|---|---|---|
| PHASEBIO PHARMACEUTICALS, INC. | Director/Board Member | 12/02/2020 |
| FULCRUM THERAPEUTICS, INC. | Chief Executive Officer | 01/07/2023 |
ReViral Ltd.
 ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | Chief Executive Officer | 10/06/2019 |
Former positions of Alexander Sapir
| Companies | Position | End |
|---|---|---|
| DOVA PHARMACEUTICALS, INC. | Chief Executive Officer | 01/12/2018 |
| UNITED THERAPEUTICS CORPORATION | Sales & Marketing | 01/05/2016 |
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Sales & Marketing | 01/01/2005 |
Training of Alexander Sapir
| Franklin & Marshall College | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| UNITED THERAPEUTICS CORPORATION | Health Technology |
| PHASEBIO PHARMACEUTICALS, INC. | Health Technology |
| FULCRUM THERAPEUTICS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Dova Pharmaceuticals, Inc.
 Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dova Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the acquisition, development and commercialization of drug candidates for rare diseases. It focuses on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist. The company was founded on March 24, 2016 and is headquartered in Durham, NC. | Health Technology |
- Stock Market
- Insiders
- Alexander Sapir
